Renal function in HCV therapy: Just another thing to ignore?
- PMID: 32352237
- DOI: 10.1111/liv.14391
Renal function in HCV therapy: Just another thing to ignore?
Comment on
-
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.Liver Int. 2020 May;40(5):1032-1041. doi: 10.1111/liv.14320. Epub 2019 Dec 26. Liver Int. 2020. PMID: 31821716 Clinical Trial.
References
REFERENCES
-
- Goodkin DA, Bieber B, Gillespie B, et al. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013;38:405-412.
-
- Zhao Q, Wen Y, Jiang Y, et al. Next generation sequencing-based investigation of potential patient-to-patient hepatitis C virus transmission during hemodialytic treatment. PLoS ONE. 2016;25(11):e0147566.
-
- Kuna L, Jakab J, Smolic R, et al. HCV extrahepatic manifestations. J Clin Transl Hepatol. 2019;7:172-182.
-
- Lee JJ, Lin MY, Chang JS, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS ONE. 2014;9:e100790.
-
- Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697-703.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
